Lyell Immunopharma (LYEL) Stock Statistics & Valuation Metrics

Lyell Immunopharma has a market cap or net worth of $170.34M. The enterprise value is -$85.33M.

Lyell Immunopharma has 15,457,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lyell Immunopharma’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -80.61%.

The current PE Ratio of Lyell Immunopharma is ―. Lyell Immunopharma’s PEG ratio is ―.

In the last 12 months, Lyell Immunopharma had revenue of 61.00K and earned -342.99M in profits. Earnings per share was -1.31.

In the last 12 months, operating cash flow was -23.59M and capital expenditures -6.88M, giving a free cash flow of -30.47M billion.

Lyell Immunopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lyell Immunopharma upcoming earnings date is Nov 11, 2025, After Close (Confirmed).

Lyell Immunopharma as a current ratio of 7.06, with Debt / Equity ratio of 14.52%

In the past 12 months, Lyell Immunopharma has paid 0.00 in taxes.

Lyell Immunopharma EV to EBITDA ratio is -16.45, with an EV/FCF ratio of -20.26.

Lyell Immunopharma has $301.18M in cash and marketable securities with $48.85M in debt, giving a net cash position of -$252.33M billion.

Gross margin is 100.00%, with operating margin of -588122.95%, and net profit margin of -562285.25%.

The average price target for Lyell Immunopharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Sell